CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that CytRx President and CEO Steven A. Kriegsman and Chief Medical Officer Daniel Levitt, M.D., Ph.D., will present at the Rodman & Renshaw Annual Global Investment Conference being held at the Grosvenor House Hotel in London on Monday, May 17, at 2:25 p.m. local time (9:25 a.m. Eastern time). The presentation will include a discussion of the Company's clinical development plans for its high-value oncology development pipeline, including up to six Phase 2 oncology clinical trials in 2010. A live webcast of the presentation will be available on the Company's Web site at www.cytrx.com, and a replay will be available for 90 days. About CytRx CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The CytRx oncology pipeline includes three programs in clinical development for cancer indications, including INNO-206, bafetinib and tamibarotene. CytRx recently announced plans to initiate Phase 2 clinical trials with its oncology candidate INNO-206 as a treatment for pancreatic cancer, gastric cancer and soft tissue sarcomas. The Company also has announced plans to initiate three Phase 2 clinical trials with bafetinib as a treatment for high-risk B-cell chronic lymphocytic leukemia (B-CLL), glioblastoma multiforme (a common and aggressive type of primary brain tumor) and advanced prostate cancer. In addition, CytRx is developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease. CytRx also maintains a 28% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ: RXII). For more information on the Company, visit www.cytrx.com.
More from Press Releases
NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling
The Supreme Court rules that previous congressional action forbidding states from legalizing sports betting was unconstitutional.
Walmart CEO: 'We Are Transforming Globally' With Flipkart
On its investor call on Wednesday morning, Walmart discusses the Flipkart deal.
March 24 Full-Day Course Offering: Professional Approach to Trading SPX
OptionsProfits, the CBOE, and Option Pit are hosting a class on March 24 that covers a wide variety of methods to trade the S&P 500.